{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:19:30Z","timestamp":1790140770093,"version":"4.0.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Concurrent achievement of symptomatic, endoscopic, and histologic remission, known as disease clearance, has been proposed as a treatment target in ulcerative colitis. Mirikizumab, an anti-interleukin-23p19 antibody, has demonstrated long-term efficacy and safety, as reported in the LUCENT Phase 3 trials (NCT03518086, NCT03524092, and NCT03519945). The current analysis evaluates the impact of mirikizumab on disease clearance and its association with other clinical and patient-reported outcomes (PROs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>LUCENT methods have previously been reported. The proportion of patients achieving disease clearance was determined through week (W)104. Association analyses were assessed between disease clearance and PROs (IBDQ, SF-36, WPAI: UC, PGRS, and PGRC), and early disease clearance and subsequent clinical outcomes (clinical, corticosteroid-free, endoscopic, histological, histologic-endoscopic, bowel urgency, stool frequency, and rectal bleeding).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportions of patients achieving disease clearance with mirikizumab at W12, W52, and W104 were 16.0%, 36.4%, and 51.3%, respectively. Mirikizumab-treated patients with disease clearance showed greater PRO improvements through W52 than those without. Early clearance at W12 was associated with significantly better clinical outcomes at later time points, except for bowel urgency remission at W52. This trend was repeated for clinical outcomes at W104 in patients who achieved disease clearance at W52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mirikizumab consistently demonstrated disease clearance across induction, maintenance, and long-term studies. The attainment of disease clearance was associated with greater improvement in PROs, and early achievement of disease clearance was associated with better long-term outcomes, including clinical remission, corticosteroid-free remission, endoscopic and histological outcomes, reduced stool frequency, and rectal bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf124","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T19:02:45Z","timestamp":1752346965000},"source":"Crossref","is-referenced-by-count":3,"title":["Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint"],"prefix":"10.1093","volume":"19","author":[{"given":"Jean-Frederic","family":"Colombel","sequence":"first","affiliation":[{"name":"Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-1090","authenticated-orcid":false,"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-4234","authenticated-orcid":false,"given":"Taku","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Paulissen","sequence":"additional","affiliation":[{"name":"Syneos Health , Morrisville, NC,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agni","family":"Dhanabal","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, Ontario,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Siegel","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center , Lebanon, NH,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, Medizinische Klinik f\u00fcr Gastroenterologie, Infektiologie und Rheumatologie , Berlin,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Redondo","sequence":"additional","affiliation":[{"name":"Medical Affairs, Eli Lilly and Company , Lisbon,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Moses","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"Center for Health Technology and Services Research (CINTESIS@RISE), Faculty of Medicine, University of Porto , Porto,","place":["Portugal"]},{"name":"Faculty of Medicine, University of Porto and ULS S\u00e3o Jo\u00e3o , Porto,","place":["Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"2025102819152526300_jjaf124-B1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/ibd\/izad159","article-title":"Disease clearance as a new outcome in ulcerative colitis: a systematic review and expert consensus","volume":"30","author":"D\u2019Amico","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152526300_jjaf124-B2","doi-asserted-by":"publisher","first-page":"1102420","DOI":"10.3389\/fmed.2022.1102420","article-title":"Disease clearance in ulcerative colitis: setting the therapeutic goals for future in the treatment of ulcerative colitis","volume":"9","author":"Ramos","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025102819152526300_jjaf124-B3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3748\/wjg.v30.i13.1801","article-title":"Disease clearance in ulcerative colitis: a new therapeutic target for the future","volume":"30","author":"Hassan","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2025102819152526300_jjaf124-B4","doi-asserted-by":"publisher","first-page":"i529","DOI":"10.1093\/ecco-jcc\/jjac190.0528","article-title":"P398 Disease clearance: a potential target for management of patients with ulcerative colitis","volume":"17","author":"Andronic","year":"2023","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025102819152526300_jjaf124-B5","doi-asserted-by":"publisher","first-page":"i398","DOI":"10.1093\/ecco-jcc\/jjab232.533","article-title":"P406 Disease clearance in patients with ulcerative colitis treated with aminosalicylates","volume":"16","author":"Nascimento","year":"2022","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025102819152526300_jjaf124-B6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/jgh.13923","article-title":"Limited uptake of ulcerative colitis \u201ctreat-to-target\u201d recommendations in real-world practice","volume":"33","author":"Bryant","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025102819152526300_jjaf124-B7","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"2025102819152526300_jjaf124-B8","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/ecco-jcc\/jjad050","article-title":"Resolving histological inflammation in ulcerative colitis with mirikizumab in the LUCENT induction and maintenance trial programmes","volume":"17","author":"Magro","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025102819152526300_jjaf124-B9","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/ibd\/izae024","article-title":"Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study","volume":"30","author":"Sands","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152526300_jjaf124-B10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/ibd\/izae004","article-title":"Extended induction and prognostic indicators of response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials","volume":"30","author":"D\u2019Haens","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102819152526300_jjaf124-B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1179\/jmt.2009.17.3.163","article-title":"Global rating of change scales: a review of strengths and weaknesses and considerations for design","volume":"17","author":"Kamper","year":"2009","journal-title":"J Man Manip Ther"},{"key":"2025102819152526300_jjaf124-B12","doi-asserted-by":"publisher","first-page":"otaf002","DOI":"10.1093\/crocol\/otaf002","article-title":"Efficacy and safety of mirikizumab in the treatment of moderately to severely active ulcerative colitis regardless of baseline modified Mayo score: results from the phase 3 LUCENT trials","volume":"7","author":"Abraham","year":"2025","journal-title":"Crohns Colitis 360"},{"key":"2025102819152526300_jjaf124-B13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/apt.16147","article-title":"Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission","volume":"52","author":"Narula","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102819152526300_jjaf124-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41575-019-0211-1","article-title":"Evolving therapeutic goals in ulcerative colitis: towards disease clearance","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025102819152526300_jjaf124-B15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2025102819152526300_jjaf124-B16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ecco-jcc\/jjaa110","article-title":"ECCO position paper: harmonization of the approach to ulcerative colitis histopathology","volume":"14","author":"Magro","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025102819152526300_jjaf124-B17","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ueg2.12288","article-title":"Ulcerative colitis: impact of early disease clearance on long-term outcomes\u2014a multicenter cohort study","volume":"10","author":"D\u2019Amico","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2025102819152526300_jjaf124-B18","doi-asserted-by":"publisher","first-page":"S305","DOI":"10.1093\/ecco-jcc\/jjab076.396","article-title":"P271 evolving targets in ulcerative colitis: defining disease clearance in the VARSITY study","volume":"15","author":"Danese","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025102819152526300_jjaf124-B19","doi-asserted-by":"publisher","first-page":"i92","DOI":"10.1093\/ecco-jcc\/jjad212.0051","article-title":"DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe ulcerative colitis: an interim analysis from the VERDICT trial","volume":"18","author":"Jairath","year":"2024","journal-title":"J Crohn\u2019s Colitis"},{"key":"2025102819152526300_jjaf124-B20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","article-title":"Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: international Delphi consensus recommendations","volume":"18","author":"Schreiber","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025102819152526300_jjaf124-B21","first-page":"11","article-title":"Risankizumab in patients with moderately to severely active ulcerative colitis in the phase 3 INSPIRE and COMMAND studies","volume":"20","year":"2024","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025102819152526300_jjaf124-B22","first-page":"9","article-title":"Risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"19","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025102819152526300_jjaf124-B23","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2025102819152526300_jjaf124-B24","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/00005176-199904001-00003","article-title":"Development and subsequent refinement of the inflammatory bowel disease questionnaire: a quality-of-life instrument for adult patients with inflammatory bowel disease","volume":"28","author":"Irvine","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf124\/63735796\/jjaf124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf124\/63735796\/jjaf124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/9\/jjaf124\/63735796\/jjaf124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T23:15:36Z","timestamp":1761693336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf124\/8198082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf124","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,13]]},"article-number":"jjaf124"}}